Haematologic outcomes and associated clinical characteristics among patients receiving Olaparib therapy in the UAE: a retrospective chart review
Our findings highlight the side effects of Olaparib therapy in terms of haematology which could be avoided. Further studies are needed to better understand the therapeutic management of Olaparib and the mitigation of haematologic complications.
Authors
- Said Abdallah Nabil (ORCID: https://orcid.org/0009-0003-2911-0190)
- Lina Wahba
- Amal Akour (ORCID: https://orcid.org/0000-0002-2789-8514)
- Sham ZainAlAbdin (ORCID: https://orcid.org/0000-0003-1331-6664)
- Salahdein Aburuz (ORCID: https://orcid.org/0000-0002-2478-3914)
- Saba Kendakji
- Mariam Ibrahim (ORCID: https://orcid.org/0000-0003-0113-1742)
Institutions
- University of Jordan (JO)
- George Washington University (US)
- United Arab Emirates University (AE)
- Tawam Hospital (AE)
- Abu Dhabi Health Services (AE)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1080/07853890.2024.2440631
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28